Patents by Inventor Erik Verner

Erik Verner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pyrazolopyrimidine compounds as kinase inhibitors
    Patent number: 8940744
    Abstract: The present disclosure provides compounds of Formula (IA) and/or pharmaceutically acceptable salts thereof that are tyrosine kinase inhibitors, in particular BTK, and are potentially useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer, inflammatory diseases such as arthritis, and the like. Also provided are pharmaceutical compositions containing such compounds and/or pharmaceutically acceptable salts thereof and processes for preparing such compounds and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: August 20, 2014
    Date of Patent: January 27, 2015
    Assignee: Principia Biopharma Inc.
    Inventors: Tim Owens, Erik Verner
  • PYRAZOLOPYRIMIDINE COMPOUNDS AS KINASE INHIBITORS
    Publication number: 20140364410
    Abstract: The present disclosure provides compounds of Formula (IA) and/or pharmaceutically acceptable salts thereof that are tyrosine kinase inhibitors, in particular BTK, and are potentially useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer, inflammatory diseases such as arthritis, and the like. Also provided are pharmaceutical compositions containing such compounds and/or pharmaceutically acceptable salts thereof and processes for preparing such compounds and pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: August 20, 2014
    Publication date: December 11, 2014
    Inventors: Tim OWENS, Erik VERNER
  • Selective inhibitors of histone deacetylase
    Patent number: 8906954
    Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of histone deacetylase 8 (HDAC8). Also described herein are methods of using such HDAC8 inhibitors, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of HDAC8 activity.
    Type: Grant
    Filed: May 20, 2013
    Date of Patent: December 9, 2014
    Assignee: Pharmacyclics, Inc.
    Inventors: Erik Verner, Sriram Balasubramanian, Joseph J. Buggy
  • Indole derivatives as inhibitors of histone deacetylase
    Patent number: 8900565
    Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of histone deacetylase 8 (HDAC8). Also described herein are methods of using such HDAC8 inhibitors, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of HDAC8 activity.
    Type: Grant
    Filed: November 21, 2012
    Date of Patent: December 2, 2014
    Assignee: Pharmacyclics, Inc.
    Inventors: Joseph J. Buggy, Sriram Balasubramanian, Erik Verner, Vincent W. F. Tai, Chang-Sun Lee
  • INHIBITORS OF BRUTON'S TYROSINE KINASE
    Publication number: 20140336206
    Abstract: Disclosed herein are pyrazolo[3,4-d]pyrimidines that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Application
    Filed: July 24, 2014
    Publication date: November 13, 2014
    Inventors: Lee HONIGBERG, Erik VERNER, Zhengying PAN
  • Inhibitors of Bruton's tyrosine kinase
    Patent number: 8883435
    Abstract: Described herein are irreversible kinase inhibitor compounds, methods for synthesizing such irreversible inhibitors, and methods for using such irreversible inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate irreversible inhibitor of a protein, including a kinase.
    Type: Grant
    Filed: March 27, 2008
    Date of Patent: November 11, 2014
    Assignee: Pharmacyclics, Inc.
    Inventors: Lee Honigberg, Erik Verner, Joseph J. Buggy, David Loury, Wei Chen
  • Inhibitors of Bruton's tyrosine kinase for the treatment of solid tumors
    Patent number: 8883803
    Abstract: Described herein are irreversible Btk inhibitor compounds, and methods for using such irreversible inhibitors in the treatment of diseases and disorders characterized by the presence or development of solid tumors.
    Type: Grant
    Filed: December 30, 2011
    Date of Patent: November 11, 2014
    Assignee: Pharmacyclics, Inc.
    Inventors: Lee Honigberg, Erik Verner, Joseph Buggy, David Loury, Wei Chen
  • INHIBITORS OF BRUTON'S TYROSINE KINASE
    Publication number: 20140275125
    Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Application
    Filed: March 22, 2013
    Publication date: September 18, 2014
    Applicant: Pharmacyclics, Inc.
    Inventors: Lee HONIGBERG, Erik VERNER, Zhengying PAN
  • INHIBITORS OF BRUTON'S TYROSINE KINASE
    Publication number: 20140243355
    Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Application
    Filed: November 13, 2013
    Publication date: August 28, 2014
    Applicant: Pharmacyclics, Inc.
    Inventors: Lee HONIGBERG, Erik Verner, Zhengying Pan
  • Inhibitors of Bruton's tyrosine kinase
    Patent number: 8809273
    Abstract: Described herein are irreversible kinase inhibitor compounds, methods for synthesizing such irreversible inhibitors, and methods for using such irreversible inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate irreversible inhibitor of a protein, including a kinase.
    Type: Grant
    Filed: December 29, 2011
    Date of Patent: August 19, 2014
    Assignee: Pharmacyclics, Inc.
    Inventors: Lee Honigberg, Erik Verner, Joseph J. Buggy, David Loury, Wei Chen
  • INHIBITORS OF BRUTON'S TYROSINE KINASE
    Publication number: 20140212485
    Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Application
    Filed: January 15, 2014
    Publication date: July 31, 2014
    Applicant: Pharmacyclics, Inc.
    Inventors: Lee HONIGBERG, Erik Verner, Zhengying Pan
  • INHIBITORS OF BRUTON'S TYROSINE KINASE
    Publication number: 20140187565
    Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Application
    Filed: November 14, 2013
    Publication date: July 3, 2014
    Applicant: Pharmacyclics, Inc.
    Inventors: Lee HONIGBERG, Erik Verner, Zhengying Pan
  • INHIBITORS OF BRUTON'S TYROSINE KINASE
    Publication number: 20140187564
    Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Application
    Filed: November 6, 2013
    Publication date: July 3, 2014
    Applicant: Pharmacyclics, Inc.
    Inventors: Lee HONIGBERG, Erik Verner, Zhengying Pan
  • Inhibitors of Bruton's tyrosine kinase
    Patent number: 8759516
    Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Grant
    Filed: July 26, 2013
    Date of Patent: June 24, 2014
    Assignee: Pharmacyclics, Inc.
    Inventors: Lee Honigberg, Erik Verner, Zhengying Pan
  • INHIBITORS OF BRUTON'S TYROSINE KINASE
    Publication number: 20140171453
    Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Application
    Filed: November 14, 2013
    Publication date: June 19, 2014
    Applicant: Pharmacyclics, Inc.
    Inventors: Lee HONIGBERG, Erik VERNER, Zhengying PAN
  • Inhibitors of bruton's tyrosine kinase
    Patent number: 8754091
    Abstract: Disclosed herein are compounds, including compounds having the structure of Formula (A), (B), (C), and (D), as described in further detail herein, that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Grant
    Filed: July 5, 2012
    Date of Patent: June 17, 2014
    Assignee: Pharmacyclics, Inc.
    Inventors: Lee Honigberg, Erik Verner, Zhengying Pan
  • INHIBITORS OF BRUTON'S TYROSINE KINASE
    Publication number: 20140163046
    Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Application
    Filed: May 9, 2013
    Publication date: June 12, 2014
    Applicant: Pharmacyclics, Inc.
    Inventors: Lee HONIGBERG, Erik VERNER, Zhengying PAN
  • INHIBITORS OF BRUTON'S TYROSINE KINASE
    Publication number: 20140163027
    Abstract: Described herein are irreversible kinase inhibitor compounds, methods for synthesizing such irreversible inhibitors, and methods for using such irreversible inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate irreversible inhibitor of a protein, including a kinase.
    Type: Application
    Filed: February 12, 2014
    Publication date: June 12, 2014
    Applicant: Pharmacyclics, Inc.
    Inventors: Erik Verner, Wei Chen
  • Inhibitors of Bruton's tyrosine kinase
    Patent number: 8748438
    Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk, such as those having the structure of Formula (A) Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Grant
    Filed: December 29, 2011
    Date of Patent: June 10, 2014
    Assignee: Pharmacyclics, Inc.
    Inventors: Lee Honigberg, Erik Verner, Zhengying Pan
  • Inhibitors of Bruton's tyrosine kinase
    Patent number: 8748439
    Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk, such as those having the structure: Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Grant
    Filed: April 18, 2012
    Date of Patent: June 10, 2014
    Assignee: Pharmacyclics, Inc.
    Inventors: Lee Honigberg, Erik Verner, Zhengying Pan